ImmunoCellular Therapeutics (IMUC) -11.5% AH after president and CEO Manish Singh resigns. The drug developer's chief scientific officer and chairman John Yu will assume the roles on an interim basis until a permanent successor is selected.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs